Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
-
Patent number: 10787507Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: February 22, 2018Date of Patent: September 29, 2020Assignee: VITAERIS INC.Inventor: Jeffrey T. L. Smith
-
Patent number: 10787706Abstract: Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences.Type: GrantFiled: October 3, 2019Date of Patent: September 29, 2020Assignee: GigaGen, Inc.Inventors: David Scott Johnson, Everett Hurteau Meyer
-
Patent number: 10781250Abstract: A refolding process of Ranibizumab is disclosed wherein the solubilized solution of heavy chain and/or light chain of Ranibizumab treated with refolding buffer under suitable conditions including pH, temperature and incubation period and the pH and temperature shift is performed at suitable interval to obtain high quality and quantity of refolded protein.Type: GrantFiled: August 17, 2016Date of Patent: September 22, 2020Assignee: Lupin LimitedInventors: Sandeep Somani, Ashish Pandey, Ashok Mishra, Rustom Sorab Mody
-
Patent number: 10781257Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 18, 2018Date of Patent: September 22, 2020Assignee: Roche Glyeart AGInventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Patent number: 10774388Abstract: Cancer biomarkers and methods of using them are disclosed.Type: GrantFiled: October 7, 2015Date of Patent: September 15, 2020Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
-
Patent number: 10774148Abstract: The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.Type: GrantFiled: February 26, 2016Date of Patent: September 15, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Takahiro Kakehi, Akinori Yamada, Yoshimasa Ishida
-
Patent number: 10765665Abstract: A formulation, especially one that is topically administered, comprising a combination of rapamcycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat any disease associated with inflammation and/or any inflammatory skin disease.Type: GrantFiled: August 19, 2016Date of Patent: September 8, 2020Inventor: Jeffrey Melin
-
Patent number: 10766954Abstract: The invention provides therapeutic antibodies and methods for treatment of diseases associated with diseases associated with aggregation of ?-synuclein, e.g., in the brain of a subject. Such methods provide administration of therapeutic antibodies to elicit a beneficial immunogenic response against aggregation of ?-synuclein. The methods are particularly useful for prophylactic and therapeutic treatment of diseases associated with the formation of Lewy bodies, e.g., Parkinson's disease.Type: GrantFiled: April 5, 2017Date of Patent: September 8, 2020Assignee: Imago Pharmaceuticals, Inc.Inventors: Irene Griswold-Prenner, Karen Chen
-
Patent number: 10766955Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.Type: GrantFiled: January 19, 2018Date of Patent: September 8, 2020Assignee: SANOFIInventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
-
Patent number: 10767232Abstract: The present disclosure provides methods for predicting responsiveness of a subject having cancer to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Further provided are methods related thereto for treating or delaying progression of cancer in a subject by administering an effective amount of an OX40 agonist to a subject. Specific biomarkers for all such methods are described herein.Type: GrantFiled: December 8, 2017Date of Patent: September 8, 2020Assignee: Genentech, Inc.Inventor: Mahrukh Huseni
-
Patent number: 10766960Abstract: The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology.Type: GrantFiled: December 26, 2013Date of Patent: September 8, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Futa Mimoto, Hitoshi Katada, Hirotake Shiraiwa
-
Patent number: 10766957Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: August 9, 2016Date of Patent: September 8, 2020Assignee: MERCK SHARP & DOHME CORPInventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
-
Patent number: 10759844Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.Type: GrantFiled: April 27, 2015Date of Patent: September 1, 2020Assignee: UCB BIOPHARMA SPRLInventor: David Paul Humphreys
-
Patent number: 10758632Abstract: Disclosed is a tumor-specific antibody and fluorophore conjugate for detecting, localizing and imaging of various tumors. Also disclosed are methods for detecting, localizing and imaging a solid tumor before or during a tumor resection surgery using the antibody-fluorophore conjugate.Type: GrantFiled: January 25, 2018Date of Patent: September 1, 2020Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Paul Yazaki, Jack Shively, Michael Bouvet, Jonathan Delong, Yuman Fong
-
Patent number: 10759834Abstract: Methods and compositions are provided concerning polypeptides with modifications that increase its binding affinity for the Fab region of an antibody. Methods include using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptides. Other embodiments concern kits, compositions, and solid supports containing the polypeptides and for using the polypeptides for isolating, detecting, purifying, measuring and quantifying Fab polypeptide.Type: GrantFiled: October 16, 2015Date of Patent: September 1, 2020Assignee: The University of ChicagoInventors: Anthony A. Kossiakoff, Lucas J. Bailey
-
Patent number: 10759867Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.Type: GrantFiled: July 6, 2012Date of Patent: September 1, 2020Assignee: GENMAB B.V.Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
-
Patent number: 10752680Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.Type: GrantFiled: May 9, 2016Date of Patent: August 25, 2020Assignee: ATHERA BIOTECHNOLOGIES ABInventor: Johan Frostegård
-
Patent number: 10752667Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R?2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.Type: GrantFiled: April 20, 2018Date of Patent: August 25, 2020Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Carla Lema Tome, Sara Ferluga, Poonam S. Sonawane
-
Patent number: 10745481Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: May 4, 2016Date of Patent: August 18, 2020Assignee: CytomX Therapeutics, Inc.Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
-
Patent number: 10745463Abstract: Means for improving the effector functions of current immunotherapeutic antibodies through targeted hyper-glycosylation of the antibody Fc region are disclosed, as well as antibody variants having hyper-glycosylated Fc regions. Fc receptor-mediated effector functions have been shown to be a critical contributor to the efficacies of numerous therapeutic antibodies currently in clinical use. Targeted hyper-glycosylation of antibodies has the potential to significantly improve current immunotherapies for cancer.Type: GrantFiled: November 18, 2014Date of Patent: August 18, 2020Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Eric J. Sundberg, Beatriz Trastoy Bello
-
Patent number: 10738103Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.Type: GrantFiled: June 15, 2017Date of Patent: August 11, 2020Assignee: Hoffmann-La Roche Inc.Inventor: Roland Beckmann
-
Patent number: 10738109Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.Type: GrantFiled: September 19, 2018Date of Patent: August 11, 2020Assignee: ICB INTERNATIONAL, INC.Inventors: Ram S. Bhatt, Rishi S. Bhatt
-
Patent number: 10736897Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, L1, L2, E, X, Y, Z, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.Type: GrantFiled: May 24, 2018Date of Patent: August 11, 2020Assignee: ARAXES PHARMA LLCInventors: Liansheng Li, Jun Feng, Tao Wu, Yuan Liu, Yi Wang, Pingda Ren, Yi Liu
-
Patent number: 10738129Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.Type: GrantFiled: December 27, 2018Date of Patent: August 11, 2020Assignee: Health Research, Inc.Inventors: Robert A. Fenstermaker, Michael J. Ciesielski
-
Patent number: 10730953Abstract: The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.Type: GrantFiled: October 22, 2019Date of Patent: August 4, 2020Assignee: AbbVie Biotherapeutics Inc.Inventors: Daniel E. H. Afar, Fiona A. Harding, Josue Samayoa
-
Patent number: 10730954Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.Type: GrantFiled: May 11, 2018Date of Patent: August 4, 2020Assignee: HARPOON THERAPEUTICS, INC.Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
-
Patent number: 10725037Abstract: Methods and composition for the screening and isolation of aglycosylated antibody Fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated Fc domains that bind to Fc receptors or preferentially bind to particular Fc receptors are described. Furthermore, the invention provides aglycosylated Fc domains that bind to Fc receptors with high affinity. Enhanced methods and media for prokaryotic based interaction screening are also provided.Type: GrantFiled: December 13, 2013Date of Patent: July 28, 2020Assignee: Research Development FoundationInventors: George Georgiou, Sang Taek Jung
-
Patent number: 10717994Abstract: The invention provides a recombinant polypeptide X—Y for enhancing cell transduction efficiency of a target agent, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Also provided is a method for enhancing cell transduction efficiency of a target agent, comprising conjugating/attaching said target agent with a recombinant polypeptide X—Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Further provided is a pharmaceutical composition comprising a therapeutic agent, wherein said therapeutic agent is modified by conjugating/attaching with a recombinant polypeptide X—Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain.Type: GrantFiled: December 15, 2016Date of Patent: July 21, 2020Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Chin-Kai Chuang, Yu-Hsiu Su, Tzuyin Lin
-
Patent number: 10711062Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 3, 2018Date of Patent: July 14, 2020Assignee: ALECTOR LLCInventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
-
Patent number: 10711056Abstract: The invention is a method for reducing the effector functions of a therapeutic neutralizing antibody by administering to the afflicted subject an effective amount of an engineered aglycosylated human monoclonal antibody containing an engineered Fc region, wherein aglycosylation of the Fc region prevents therapeutic antibody-mediated cell activation, inflammation, C1q binding to the antibody and antibody triggered classical pathway activation.Type: GrantFiled: December 28, 2012Date of Patent: July 14, 2020Assignee: NOVELMED THERAPEUTICS, INC.Inventor: Rekha Bansal
-
Patent number: 10711060Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: GrantFiled: December 1, 2017Date of Patent: July 14, 2020Assignees: NOVARTIS AG, Immutep S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 10703824Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-binding fragments and a heterologous agent. The disclosure further provides methods for making and using the antibodies, antigen-binding fragments and conjugates, including humanized antibodies.Type: GrantFiled: March 4, 2019Date of Patent: July 7, 2020Assignee: Valerion Therapeutics, LLCInventors: Dustin D. Armstrong, Jeffrey C. Way
-
Patent number: 10703818Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: January 31, 2017Date of Patent: July 7, 2020Assignee: GENMAB A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
-
Patent number: 10696734Abstract: Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.Type: GrantFiled: August 29, 2016Date of Patent: June 30, 2020Assignee: WISCONSIN ALUMNI RESEARCG FOUNDATIONInventors: Jordan Marshall Sand, Mark Eric Cook
-
Patent number: 10695333Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.Type: GrantFiled: November 29, 2018Date of Patent: June 30, 2020Assignee: Novartis AGInventors: Tinya Abrams, Larry Alexander Gaither
-
Patent number: 10696745Abstract: The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.Type: GrantFiled: June 11, 2015Date of Patent: June 30, 2020Inventors: Yong Zheng, Jing Li, Zhisheng Chen
-
Patent number: 10689463Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.Type: GrantFiled: December 19, 2014Date of Patent: June 23, 2020Assignee: JIUZHITANG CO., LTD.Inventors: Jinhua Zhao, Jinxing He, Mingyi Wu, Zhiwen Liu, Na Gao, Longyan Zhao, Zi Li, Feng Lu, Li Xu, Chuang Xiao, Lian Yang, Jun Chen, Lutan Zhou, Wenlie Peng, Jikai Liu
-
Patent number: 10688180Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.Type: GrantFiled: September 13, 2017Date of Patent: June 23, 2020Assignees: BRISTOL-MYERS SQUIBB COMPANY, INNATE PHARMAInventors: Robert F. Graziano, Ashok K. Gupta, Su Young Kim, Jon Wigginton, Pascale Andre
-
Patent number: 10689459Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.Type: GrantFiled: December 10, 2015Date of Patent: June 23, 2020Assignees: Novartis AG, The General Hospital CorporationInventors: Qing Sheng, Rakesh K. Jain, Vasileios Askoxylakis, Gino B. Ferraro, Dai Fukumura, David P. Kodack
-
Patent number: 10690676Abstract: This document relates to methods for quantifying antibody therapeutics using mass spectrometry techniques.Type: GrantFiled: July 29, 2015Date of Patent: June 23, 2020Assignee: Mayo Roundation for Medical Education and ResearchInventors: David R. Barnidge, Maria Alice Vieira Willrich, David L. Murray, Melissa R. Snyder
-
Patent number: 10689443Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.Type: GrantFiled: March 23, 2018Date of Patent: June 23, 2020Assignee: PRECISION BIOLOGICS, INC.Inventors: Xue-Ping Wang, Philip M. Arlen
-
Patent number: 10683547Abstract: A method relates to epigenetic markers and their diagnostic and predictive value for respiratory allergy. The method can include assaying a test sample from the patient for a DNA hypermethylation or hypomethylation of at least GLI2 region, in which hypermethylation or hypomethylation of the gene region in the test sample indicates or predicts a respiratory allergy in the patient.Type: GrantFiled: May 27, 2016Date of Patent: June 16, 2020Assignee: VITO NVInventors: Patrick de Boever, Sabine Langie
-
Patent number: 10675349Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.Type: GrantFiled: October 6, 2015Date of Patent: June 9, 2020Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
-
Patent number: 10676525Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 3, 2018Date of Patent: June 9, 2020Assignee: ALECTOR LLCInventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
-
Patent number: 10669339Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: May 31, 2019Date of Patent: June 2, 2020Assignee: CYTOMX THERAPEUTICS, INC.Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
-
Patent number: 10669344Abstract: The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.Type: GrantFiled: July 28, 2017Date of Patent: June 2, 2020Assignee: Janssen Biotech, Inc.Inventors: Anthony Armstrong, Mark Chiu, Di Zhang
-
Patent number: 10669346Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: May 9, 2018Date of Patent: June 2, 2020Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 10669328Abstract: A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1?1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1?1 domain by the CH1 domain from a human IgG2 (CH1?2), IgG3 (CH1?3) or IgG4 (CH1?4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (?)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.Type: GrantFiled: November 11, 2014Date of Patent: June 2, 2020Assignee: OGD2 PHARMAInventors: Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
-
Patent number: 10662250Abstract: The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. The object of the invention was to create an efficient and safe universal antitumor agent, the production of which effective, quick and easy. This problem is solved by the proposed humanized monoclonal antibody specific to syndecan-1, of the IgG4 isotype, or with IgG3 fragments and amino acid substitutions for the increase the antibody half-life, characterized by a definite combination of the calculated and created by the authors amino acid and nucleotide sequences, which is used as a self-acting substance for the therapy of tumor diseases. Nucleotide sequences additionally contain a fragment coding for a signal secretory sequence at the N-terminus, and are codon-optimized to increase antibody production in mammalian cells.Type: GrantFiled: July 21, 2016Date of Patent: May 26, 2020Inventors: Ilya Vladimirovich Dukhovlinov, Anton Iosifovich Orlov, Mark Borisovich Balazovskiy
-
Patent number: 10660890Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.Type: GrantFiled: October 24, 2014Date of Patent: May 26, 2020Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Sergio A. Gradilone, Nicholas F. LaRusso